GlassScriptPhysician profile
Sharon J Bae
NPI 1346211372
$2,697.35
in general payments reported to CMS, 2019-2025
30 companies · $41.68 in 2025
The $41.68 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $649 · 2021: $407 · 2022: $133 · 2023: $71.96 · 2024: $39.04 · 2025: $41.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $103 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $102.68 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $594.49 | 2019-2021 | |
| Amgen INC. | $413.79 | 2019-2022 | |
| Abbvie INC. | $216.04 | 2019-2025 | |
| Sobi, INC | $163.31 | 2019-2022 | |
| Janssen Biotech, INC. | $145.10 | 2019-2020 | |
| Genzyme Corporation | $137.69 | 2019-2020 | |
| Sanofi Pasteur INC. | $108.62 | 2019-2021 | |
| Celgene Corporation | $81.59 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $78.39 | 2019-2023 | Saphnelo |
| Currax Pharmaceuticals LLC | $78.05 | 2019-2023 | Nexletol |
| Radius Health, INC. | $73.58 | 2020-2024 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.62 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.75 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $45.00 | 2019 | |
| Mallinckrodt Enterprises LLC | $44.98 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $44.95 | 2019 | |
| Alexion Pharmaceuticals, INC. | $44.12 | 2019 | |
| Daiichi Sankyo INC. | $39.79 | 2019 | |
| Bausch Health US, LLC | $31.21 | 2019 | |
| Merck Sharp & Dohme LLC | $30.57 | 2019 | |
| Allergan, INC. | $28.70 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.93 | 2019-2020 | |
| Eisai INC. | $24.05 | 2021 | |
| Horizon Therapeutics Plc | $21.94 | 2022 | |
| Medexus Pharma, INC. | $20.90 | 2019 | |
| Therapeuticsmd, INC. | $19.49 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.90 | 2019 | |
| Exact Sciences Corporation | $18.21 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $17.30 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Bae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.